Ariunaa Bayanjargal

Ariunaa Bayanjargal

Auto-generated profile, based on publicly available information

Ariunaa Bayanjargal

Center for Childhood Cancer, Abigail Wexner Research Institute at Nationwide Children’s Hospital

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
GRGalen C. Rask
Galen C. Rask
CTCenny Taslim
Cenny Taslim
ABAriunaa Bayanjargal
Ariunaa Bayanjargal
MCMatthew V. Cannon
Matthew V. Cannon
JSJulia Selich-Anderson
Julia Selich-Anderson
ETEmily R. Theisen
Emily R. Theisen
Genes encoding the RNA-binding proteins F US, E WSR1, and T AF15 (FET proteins) are involved in chromosomal translocations in rare sarcomas. FET-rearranged sarcomas are often aggressive malignancies affecting patients of all ages. New therapies are needed. These translocations fuse the 5’ portion of the FET gene with a 3’ partner gene encoding a transcription factor (TF). The resulting fusion proteins are oncogenic TFs with a FET protein low complexity domain (LCD) and a DNA binding domain. FET fusion proteins have proven stubbornly difficult to target directly and promising strategies target critical co-regulators. One candidate is lysine specific demethylase 1 (LSD1). LSD1 is recruited by multiple FET fusions, including EWSR1::FLI1. LSD1 promotes EWSR1::FLI1 activity and treatment with the noncompetitive inhibitor SP-2509 blocks EWSR1::FLI1 transcriptional function. A similar molecule, seclidemstat (SP-2577), is currently in clinical trials for FET-rearranged sarcomas ( NCT03600649 ). However, whether seclidemstat has pharmacological activity against FET fusions has not been demonstrated. Here, we evaluate the in vitro potency of seclidemstat against multiple FET-rearranged sarcoma cell lines, including Ewing sarcoma, desmoplastic small round cell tumor, clear cell sarcoma, and myxoid liposarcoma. We also define the transcriptomic effects of seclidemstat treatment and evaluated the activity of seclidemstat against FET fusion transcriptional regulation. Seclidemstat showed potent activity in cell viability assays across FET-rearranged sarcomas and disrupted the transcriptional function of all tested fusions. Though epigenetic and targeted inhibitors are unlikely to be effective as a single agents in the clinic, these data suggest seclidemstat remains a promising new treatment strategy for patients with FET-rearranged sarcomas. SIGNIFICANCE: Here, we show the noncompetitive inhibitor, seclidemstat, has in vitro activity against multiple FET fusion proteins that cause a number of rare and aggressive sarcomas. These data represent one of the largest analyses of FET fusion activity across multiple malignancies and are a valuable resource for those studying FET-rearranged sarcomas.

25 August 2025 in Cancer Research Communications
Verified
Journal Article
Open access
GRGalen C. Rask
Galen C. Rask
CTCenny Taslim
Cenny Taslim
ABAriunaa Bayanjargal
Ariunaa Bayanjargal
RDRachel D. Dreher
Rachel D. Dreher
MCMatthew V. Cannon
Matthew V. Cannon
ETEmily R. Theisen
Emily R. Theisen
Genes encoding the RNA-binding proteins FUS, EWSR1, and TAF15 (FET proteins) are involved in chromosomal translocations in rare sarcomas. The encoded fusion oncoproteins typically include a DNA binding domain and function as oncogenic transcription factors. FET-rearranged sarcomas are often aggressive malignancies affecting patients of all ages. Oncogenic fusion TFs are challenging to target directly and new therapies are needed. Treatment with the small molecule SP-2509 results in reversal of the transcriptional activity of the FET fusion that causes Ewing sarcoma, EWSR1::FLI1. A similar molecule, seclidemstat (SP-2577), is currently in clinical trials for FET-rearranged sarcomas (NCT03600649), but its pharmacological activity in FET fusion positive sarcomas has not been demonstrated. We found potent seclidemstat cytotoxicity against both FET-rearranged and other fusion-positive sarcoma cell lines in vitro, including Ewing sarcoma, desmoplastic small round cell tumor, clear cell sarcoma, myxoid liposarcoma, and fusion-positive rhabdomyosarcoma. We also define transcriptomic effects of seclidemstat with bulk RNA-seq. Seclidemstat recapitulated much of SP-2509 transcriptional activity in Ewing sarcoma. Widespread transcriptional changes were seen in all tested cell lines after seclidemstat treatment, regardless of the fusion protein expressed. This included reversal of FET-fusion transcriptional signatures for EWSR1::WT1, EWSR1::ATF1, and EWSR1::ERG. Though novel inhibitors are unlikely to display single-agent efficacy in the clinic, these data suggest seclidemstat remains a promising new treatment strategy for patients with FET-rearranged and other fusion positive sarcomas.

15 June 2026 in eLife
Verified
Journal Article
Open access
ABAriunaa Bayanjargal
Ariunaa Bayanjargal
CTCenny Taslim
Cenny Taslim
ISIftekhar A Showpnil
Iftekhar A Showpnil
JSJulia Selich-Anderson
Julia Selich-Anderson
JCJesse C Crow
Jesse C Crow
ETEmily Rose Theisen
Emily Rose Theisen
Ewing sarcoma is the second most common bone cancer in children and young adults. In 85% of patients, a translocation between chromosomes 11 and 22 results in a potent fusion oncoprotein, EWSR1::FLI1. EWSR1::FLI1 is the only genetic alteration in an otherwise unaltered genome of Ewing sarcoma tumors. The EWSR1 portion of the protein is an intrinsically disordered domain involved in transcriptional regulation by EWSR1::FLI1. The FLI portion of the fusion contains a DNA binding domain shown to bind core GGAA motifs and GGAA repeats. A small alpha-helix in the DNA binding domain of FLI1, DBD-α4 helix, is critical for the transcription function of EWSR1::FLI1. In this study, we aimed to understand the mechanism by which the DBD-α4 helix promotes transcription and therefore oncogenic transformation. We utilized a multi-omics approach to assess chromatin organization, active chromatin marks, genome binding, and gene expression in cells expressing EWSR1::FLI1 constructs with and without the DBD-α4 helix. Our studies revealed DBD-α4 helix is crucial for cooperative binding of EWSR1::FLI1 at GGAA microsatellites. This binding underlies many aspects of genome regulation by EWSR1::FLI1, such as formation of topologically associated domains (TADs), chromatin loops, enhancers, and productive transcription hubs.

31 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAriunaa Bayanjargal
Ariunaa Bayanjargal
CTCenny Taslim
Cenny Taslim
ISIftekhar A. Showpnil
Iftekhar A. Showpnil
JSJulia Selich-Anderson
Julia Selich-Anderson
JCJesse C. Crow
Jesse C. Crow
ETEmily R. Theisen
Emily R. Theisen
Ewing sarcoma is the second most common bone cancer in children and young adults. In 85% of patients, a translocation between chromosomes 11 and 22 results in a potent fusion oncoprotein, EWS::FLI. EWS::FLI is the only genetic alteration in an otherwise unaltered genome of Ewing sarcoma tumors. The EWS portion of the protein is an intrinsically disordered domain involved in transcriptional regulation by EWS::FLI. The FLI portion of the fusion contains a DNA binding domain shown to bind core GGAA motifs and GGAA repeats. A small alpha-helix in the DNA binding domain of FLI, DBD-α4 helix, is critical for the transcription function of EWS::FLI. In this study, we aimed to understand the mechanism by which the DBD-α4 helix promotes transcription, and therefore oncogenic transformation. We utilized a multi-omics approach to assess chromatin organization, active chromatin marks, genome binding, and gene expression in cells expressing EWS::FLI constructs with and without DBD-α4 helix. Our studies revealed DBD-α4 helix is crucial for cooperative binding of EWS::FLI at GGAA microsatellites. This binding underlies many aspects of genome regulation by EWS::FLI such as formation of TADs, chromatin loops, enhancers and productive transcription hubs.

1 March 2026 in Cancer Research Communications
Verified
Journal Article
Open access
RDRachel D. Dreher
Rachel D. Dreher
CTCenny Taslim
Cenny Taslim
IMIra Miller
Ira Miller
JSJohn W. Sherman
John W. Sherman
ABAriunaa Bayanjargal
Ariunaa Bayanjargal
ETEmily R. Theisen
Emily R. Theisen
Lysine-specific demethylase 1 (LSD1), encoded by the gene KDM1A, is overexpressed and correlates with poor patient prognosis in Ewing sarcoma. LSD1 and the pathognomonic fusion oncoprotein, EWSR1::FLI1, colocalize throughout the genome, suggesting that LSD1 is a critical co-regulator driving the progression of Ewing sarcoma. However, therapeutic targeting of LSD1 by competitive and noncompetitive inhibitors has yielded mixed results. Irreversible, enzymatic inhibition seems ineffective, but reversible noncompetitive inhibition has predominant off-target mechanisms, leaving open the question of LSD1 function in Ewing sarcoma. In this study, we take a robust approach through multiple methods of depletion in multiple Ewing sarcoma cell lines to define enzymatic and nonenzymatic contributions of LSD1 to transcriptional regulation. We define a core set of 22 genes that are commonly repressed by LSD1 in all cell lines and that repression of these genes downregulates synapse functioning and e-cadherin target genes. Derepression of these genes with LSD1 loss is an early and sustained genotype in all cell lines tested. We further define distinct gene sets in each cell line that are regulated by enzymatic and nonenzymatic LSD1 activity and find repression of e-cadherin target genes to be nonenzymatically regulated. This finding supports the growing body of evidence that in addition to their canonical catalytic activity, chromatin regulatory enzymes serve essential noncanonical roles as well. Furthermore, we uncovered evidence through use of the irreversible inhibitor OG-L002 that 2D cytotoxicity and proliferation assays may be insufficient to determine Ewing sarcoma response to LSD1 inhibition. Significance: In this study, we address a long-standing question in the field surrounding LSD1 and define the distinct enzymatic and nonenzymatic functions of LSD1 in Ewing sarcoma. In doing so, we have created a robust data set using genetic and pharmacologic techniques in multiple models to thoroughly characterize LSD1 function in Ewing sarcoma cell lines.

18 March 2026
Verified
Other
Open access
RDRachel D. Dreher
Rachel D. Dreher
CTCenny Taslim
Cenny Taslim
IMIra Miller
Ira Miller
JSJohn W. Sherman
John W. Sherman
ABAriunaa Bayanjargal
Ariunaa Bayanjargal
ETEmily R. Theisen
Emily R. Theisen
Principal Component Analysis of OG-L002 treatment in A673, CHP-100, and TTC-466 cells.